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Regulation of glucagon-like peptide-1
sensitivity by gut microbiota dysbiosis
Gut hormonal substances released in
response to nutrients include incretins,
gastric inhibitory polypeptide and gluca-
gon-like peptide-1 (GLP-1). Together,
incretins are responsible for 50–60% of
postprandial insulin secretion. Oral glu-
cose administration leads to greater insu-
lin release from pancreatic islets than
intravenous glucose loading that yields
equivalent blood glucose levels; this phe-
nomenon is called the incretin effect. It
has been reported that the incretin effect
is markedly impaired in individuals with
type 2 diabetes mellitus. The impaired
incretin effect in type 2 diabetes patients
has been found to be characterized by an
almost complete loss of insulin secretion
in response to gastric inhibitory polypep-
tide and a reduced insulinotropic potency
of GLP-1. Several studies reported a
marked reduction in postprandial plasma
GLP-1 levels in type 2 diabetes patients
compared with healthy individuals, sug-
gesting that a lower level of GLP-1 secre-
tion might contribute to the impaired
incretin effect in type 2 diabetes. How-
ever, a meta-analysis of 22 trials showed
that patients with type 2 diabetes do not
generally show reduced GLP-1 secretion
in response to an oral glucose tolerance
test or meal test, although deteriorating
glycemic control might be associated
with reduced GLP-1 secretion1. In any
case, supraphysiological doses of GLP-1
are effective in type 2 diabetes patients;
thus, GLP-1 receptor (GLP-1R) agonism
might represent an attractive pharmaco-
logical strategy for diabetes treatment.
However, it is observed in clinical prac-
tice that GLP-1-based therapies do not
always achieve the intended therapeutic
outcomes in all patients with type 2
diabetes. Furthermore, some patients
have to discontinue treatment because of
a lack of efﬁcacy, which deﬁnes a state of
GLP-1 resistance.
Accumulating evidence has shown that
differences in the structure, function and
diversity of the human gut microbiota
have implications for human health and
disease. Recent studies have shown that
the immensely diverse gut microbiota
contributes to the pathogenesis of obesity
and type 2 diabetes2. Microbial metabo-
lites regulate metabolism in different tis-
sues. Gram-negative bacteria-derived
lipopolysaccharide promotes macrophage
recruitment and polarization in white
adipose tissue, inducing inﬂammation
through Toll-like receptor 4. Short-chain
fatty acids, which are fermentation prod-
ucts of the gut microbiota, serve as an
energy source in enterocytes and also
stimulate intestinal gluconeogenesis. Sec-
ondary bile acids (lithocholic acid and
deoxycholic acid) derived from the
microbiota promote thermogenesis in
brown adipose tissue, thus increasing
energy expenditure. The gut microbiota
induces signaling through farnesoid X
receptor in the liver and intestine by
metabolizing a natural farnesoid X recep-
tor antagonist, tauro-beta-muricholic
acid, reducing bile acid synthesis and
altering fatty acid metabolism. Short-
chain fatty acids and secondary bile acids
(lithocholic acid and deoxycholic acid)
are involved in stimulating GLP-1 secre-
tion from enteroendocrine L-cells.
In a recent study, Grasset et al.3
showed that gut microbiota dysbiosis
caused GLP-1 resistance in two types of
high-fat diet-fed mice with impaired glu-
cose tolerance. They clearly showed that
the dysbiosis reduced expression of GLP-
1R and neuronal nitric oxide synthase
(nNOS) in the enteric nervous system
and hampered GLP-1-induced nitric
oxide (NO) production through a pattern
recognition receptor-dependent mecha-
nism, hence preventing activation of the
gut–brain–periphery axis for control of
insulin secretion and gastric emptying
(Figure 1). These results provide new
insight into the role of the gut microbiota
in maintaining normal metabolic condi-
tions by regulating GLP-1 biology.
One of the remarkable ﬁndings of the
study was that GLP-1 unresponsiveness
was far more severe in lean diabetic mice
fed a high-fat carbohydrate-free diet
(HFD) than in obese diabetic mice fed a
high-carbohydrate HFD. Because meal
composition signiﬁcantly affects the gut
microbiota, the difference in the extent of
GLP-1 sensitivity between the two mouse
models might have resulted from varia-
tions in the ileum bacteria. Venn analyses
of pathway modules showed that there
were 25 common pathways enriched in
both the high-carbohydrate HFD-fed and
HFD-fed groups, and 19 pathway mod-
ules uniquely enriched in the HFD-fed
mice compared with the high-carbohy-
drate HFD-fed mice. Using prediction
algorithms, Grasset et al.3 suggested that
bacterial pathways related to amino acid
metabolism and transport system mod-
ules could be involved in GLP-1 resis-
tance. However, the speciﬁc mechanism
by which gut microbiota dysbiosis in
HFD-fed mice reduces GLP-1R expres-
sion in the enteric nervous system
remains to be elucidated. Furthermore, it
should be noted that the dysbiosis
observed in HFD-fed mice was possibly
speciﬁc to the extreme meal composition
applied in that study; thus, the severe
GLP-1 resistance observed in HFD-fed
diabetic mice is not necessarily recapitu-
lated in human diabetes.
In a previous report, it was shown that
long-term HFD intake caused a
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remarkable loss of intestinal myenteric
neurons in mice as a result of a lack of
energy substrates, reduced acetylcholine
synthesis, membrane deterioration and
oxidative stress4. Grasset et al.3 showed
that gut microbiota dysbiosis in HFD-fed
mice is responsible for the loss of enteric
neurons, impaired NO production and
subsequent GLP-1 resistance. It has been
generally assumed that NO produced by
nNOS in enteric neurons has protective
effects that outweigh any damaging effect
of this free radical. Therefore, it is possi-
ble that the impaired NO production as
a result of reduced nNOS expression in
enteric neurons is attributable to an
extensive loss of intestinal myenteric neu-
rons in HFD-fed mice.
Grasset et al.3 showed that insulin
secretion and gastric emptying inhibition
in response to GLP-1 were impaired by
vagotomy or by cisplatin-induced enteric
neuropathy. In contrast, energy intake in
vagotomized mice and cisplatin-treated
mice was comparable with that in control
mice, showing that insulin secretion and
gastric emptying inhibition in response to
GLP-1 are tightly dependent on a func-
tional gut–brain–periphery axis, whereas
food intake regulation is not. However,
HFD-fed mice were resistant not only to
GLP-1-induced insulin secretion and gas-
tric emptying inhibition, but also to GLP-
1-induced suppression of food intake.
Therefore, it is supposed that the arcuate
and paraventricular nuclei, the hypothala-
mic feeding centers in which GLP-1R is
expressed, could be involved in GLP-1
unresponsiveness in HFD-fed mice. How-
ever, GLP-1R expression and GLP-1
responsiveness in the arcuate and
paraventricular nuclei under high-fat diet-
ary perturbations have not yet been
examined.
It has been reported that L-arginine is a
GLP-1 secretagogue, and that improve-
ment of glucose tolerance by oral
L-arginine administration is dependent on
GLP-1R signaling5. Interestingly, in HFD-
fed mice with severe GLP-1 resistance,
glucose-induced insulin secretion was
increased by acute and chronic treatment
with L-arginine, a substrate of nNOS, sug-
gesting improved GLP-1 sensitivity. These
ﬁndings raise the intriguing possibility that
L-arginine supplementation might beneﬁt
glucose tolerance by improving both the
postprandial GLP-1 response and GLP-1
sensitivity in type 2 diabetes patients.
Gut microbiota is attracting attention
as a potential target for therapeutic
intervention. A deeper understanding of
how gut microbiota dysbiosis contributes
to the pathophysiology of obesity and
diabetes might provide a novel therapeu-
tic approach for diabetes and some clues
to overcome the difﬁculties in diabetes
treatment.
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Figure 1 | Glucagon-like peptide-1 (GLP-1) resistance caused by gut microbiota dysbiosis. Gut microbiota dysbiosis reduces expression of GLP-1
receptor (GLP-1R) and neuronal nitric oxide synthase (nNOS) in the enteric nervous system, and hampers GLP-1-induced nitric oxide (NO)
production through a pattern recognition receptor (PRR)-dependent mechanism, hence preventing activation of the gut–brain–periphery axis for
control of insulin secretion and gastric emptying. [Colour figure can be viewed at wileyonlinelibrary.com]
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